페이즈알엑스(PZRXQ)는 PINK에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.00 (+0.00%), 시가총액 $1,169.
PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder programs under development include PRX-OTC to treat ornithine transcarbamylase deficiency; PRX-ASL to treat argininosuccinate lyase deficiency; and PRX-ASS1 to treat argininosuccinate synthetase deficiency. PhaseRx, Inc., was incorporated in 2006 and is headquartered in Seattle, Washington.
페이즈알엑스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
페이즈알엑스의 현재 주가는 $0.00 (+0.00%)입니다. XTS에서 시세와 차트를 확인할 수 있습니다.
페이즈알엑스의 시가총액은 약 $1,169입니다.
PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement…